Anavex Life Sciences Corporation

AVXL

Find Out if You Qualify for a Financial Reward by filling out the form below.

Lead Plaintiff Deadline:
May 13, 2024

Days Left:
-30

calendar

Anavex Life Sciences Corporation Form












Stock Fraud Law Center does not share your information with others. There is no cost or obligation for you to submit.

Allegations

The complaint alleges that on December 2, 2022, AVXL announced positive topline results from its Phase 2b/3 ANAVEX®2-73-AD-004 clinical trial of oral ANAVEX®2-73 (blarcamesine) for the treatment of mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) and mild AD (collectively known as early AD). ANAVEX®2-73 met the primary endpoints ADAS-Cog1 and ADCS-ADL2 and key secondary endpoint CDR-SB3 with statistically significant results. An analyst questioned the Company’s claim noting “there are several key factors that point us to believe the data is provocative, but not yet compelling, given the choice of statistical analyses and other trial design/conduct ‘complexifiers’.” Additionally, a biotech journalist commented on AVXL’s findings stating “[w]hat sets Anavex apart from all the other biotechs on my radar screen is its habit of shifting the goalposts on clinical trials…Anavex announced “positive” outcomes from studies of its drug called blarcamesine — except the results were derived from efficacy endpoints that were not part of the original study designs.” Following this news, AVXL’s stock price fell by $2.47 per share, or approximately 20% to close at $9.58. Further on January 3, 2024, AVXL announced that results from its Phase 2/3 EXCELLENCE clinical trial for its candidate ANAVEX®2-73 in pediatric patients with Rett syndrome failed to show statistical significance towards its primary endpoints. Biotech analysts commented that “the negative study outcome was never in doubt…Anavex is a serial dissembler of clinical trial results.” Following this news, AVXL’s stock price fell by $3.26 per share, or approximately 35%.

Eligibility

In order to be included in the lawsuit, you must have incurred a loss on shares of Anavex Life Sciences purchased or acquired during the class period listed above.

Lead Plaintiff Deadline

If you suffered a loss in Anavex Life Sciences during the relevant time frame, you have until May 13, 2024 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Active Cases

Ticker Symbol Company Name Join Deadline Join
PERI Perion Network Ltd. June 17, 2024 Join
ASTS AST SpaceMobile, Inc. June 17, 2024 Join
SHCR Sharecare, Inc. June 18, 2024 Join
GDRX GoodRx Holdings, Inc. June 21, 2024 Join
LNC Lincoln National Corporation June 24, 2024 Join
CMP Compass Minerals International, Inc. June 24, 2024 Join
ADSK Autodesk, Inc. June 24, 2024 Join
AKRO Akero Therapeutics, Inc. June 25, 2024 Join
EXAI Exscientia plc June 25, 2024 Join
EXAI Exscientia plc June 25, 2024 Join
MBUU Malibu Boats, Inc. June 28, 2024 Join
GL Globe Life Inc. f/k/a Torchmark Corporation July 01, 2024 Join
EQIX Equinix, Inc. July 01, 2024 Join
INTC Intel Corporation July 02, 2024 Join
ALT Altimmune, Inc. July 05, 2024 Join
AXTI AXT, Inc. July 05, 2024 Join
LI Li Auto Inc. July 09, 2024 Join
SPT Sprout Social, Inc. July 12, 2024 Join
NARI Inari Medical, Inc. July 12, 2024 Join
UNH UnitedHealth Group Inc. July 15, 2024 Join
TDOC Teladoc Health, Inc. July 16, 2024 Join
VSTS Vestis Corporation July 16, 2024 Join
CMBM Cambium Networks Corporation July 22, 2024 Join
BIIB Biogen Inc. July 22, 2024 Join
FSLY Fastly, Inc. July 23, 2024 Join
ENPH Enphase Energy, Inc. July 29, 2024 Join
RIVN Rivian Automotive, Inc. July 30, 2024 Join
HTZ Hertz Global Holdings, Inc. July 30, 2024 Join
HUM Humana Inc. August 02, 2024 Join
MRNS Marinus Pharmaceuticals, Inc. August 05, 2024 Join
GRTS Gritstone bio, Inc. August 06, 2024 Join
RBLX Roblox Corporation August 12, 2024 Join